Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
5.06% $4.57
America/New_York / 27 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 123.51 mill |
EPS: | -2.96 |
P/E: | -1.540 |
Earnings Date: | Jun 25, 2024 |
SharesOutstanding: | 27.03 mill |
Avg Daily Volume: | 0.272 mill |
RATING 2024-03-27 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.540 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.26x |
Company: PE -1.540 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.981 (-56.65%) $-2.59 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 4.28 - 4.86 ( +/- 6.28%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Rotunno Mary L. | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Gin Jerry B | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Fitzpatrick Margaret M | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Curley Joanne | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Cunningham Ann Michelle | Buy | 12 500 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
97.90 |
Last 94 transactions |
Buy: 11 348 392 | Sell: 716 774 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $4.57 (5.06% ) |
Volume | 0.246 mill |
Avg. Vol. | 0.272 mill |
% of Avg. Vol | 90.38 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:28 | buy | $4.94 | N/A | Active |
---|
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.